Daniil Gataulin
Stock Analyst at Chardan Capital
(4.71)
# 186
Out of 5,182 analysts
134
Total ratings
59.35%
Success rate
32.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGTX Cognition Therapeutics | Maintains: Buy | $4 | $0.86 | +365.01% | 9 | Mar 27, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Buy | $35 | $9.34 | +274.73% | 8 | Mar 27, 2026 | |
| OCGN Ocugen | Maintains: Buy | $7 | $1.87 | +274.33% | 17 | Mar 25, 2026 | |
| ZURA Zura Bio | Maintains: Buy | $10 → $11 | $5.60 | +96.43% | 4 | Mar 23, 2026 | |
| ANNX Annexon | Maintains: Buy | $16 | $6.14 | +160.59% | 2 | Mar 20, 2026 | |
| CRVO CervoMed | Maintains: Buy | $15 → $21 | $4.03 | +421.09% | 9 | Mar 18, 2026 | |
| IRD Opus Genetics | Maintains: Buy | $9 → $11 | $5.50 | +100.00% | 4 | Mar 12, 2026 | |
| QURE uniQure | Maintains: Buy | $16 → $31 | $16.30 | +90.18% | 13 | Mar 9, 2026 | |
| EYPT EyePoint | Maintains: Buy | $27 → $29 | $14.23 | +103.79% | 13 | Mar 4, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 | $0.22 | +350.05% | 12 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $9.30 | +125.81% | 5 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $50 | $8.96 | +458.04% | 16 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.07 | +213.01% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 | $33.90 | +79.94% | 7 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 | $42.36 | -66.95% | 4 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 | $27.19 | +87.57% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,200 | $3.94 | +55,737.56% | 1 | Mar 7, 2024 |
Cognition Therapeutics
Mar 27, 2026
Maintains: Buy
Price Target: $4
Current: $0.86
Upside: +365.01%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Buy
Price Target: $35
Current: $9.34
Upside: +274.73%
Ocugen
Mar 25, 2026
Maintains: Buy
Price Target: $7
Current: $1.87
Upside: +274.33%
Zura Bio
Mar 23, 2026
Maintains: Buy
Price Target: $10 → $11
Current: $5.60
Upside: +96.43%
Annexon
Mar 20, 2026
Maintains: Buy
Price Target: $16
Current: $6.14
Upside: +160.59%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $15 → $21
Current: $4.03
Upside: +421.09%
Opus Genetics
Mar 12, 2026
Maintains: Buy
Price Target: $9 → $11
Current: $5.50
Upside: +100.00%
uniQure
Mar 9, 2026
Maintains: Buy
Price Target: $16 → $31
Current: $16.30
Upside: +90.18%
EyePoint
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $29
Current: $14.23
Upside: +103.79%
Outlook Therapeutics
Feb 18, 2026
Maintains: Neutral
Price Target: $1
Current: $0.22
Upside: +350.05%
Feb 18, 2026
Maintains: Buy
Price Target: $21
Current: $9.30
Upside: +125.81%
Feb 10, 2026
Maintains: Buy
Price Target: $52 → $50
Current: $8.96
Upside: +458.04%
Dec 23, 2025
Initiates: Buy
Price Target: $19
Current: $6.07
Upside: +213.01%
Nov 17, 2025
Maintains: Buy
Price Target: $61
Current: $33.90
Upside: +79.94%
Nov 17, 2025
Maintains: Neutral
Price Target: $14
Current: $42.36
Upside: -66.95%
Nov 11, 2025
Maintains: Buy
Price Target: $51
Current: $27.19
Upside: +87.57%
Mar 7, 2024
Maintains: Buy
Price Target: $2,200
Current: $3.94
Upside: +55,737.56%